$4.24
0.00% yesterday
Nasdaq, Sep 27, 10:14 pm CET
ISIN
US8051111016
Symbol
SVRA
Sector
Industry

Savara, Inc. Stock price

$4.24
-0.08 1.85% 1M
-0.61 12.58% 6M
-0.46 9.79% YTD
+0.52 13.98% 1Y
+2.95 228.68% 3Y
+1.44 51.43% 5Y
-34.68 89.11% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.00 0.00%
ISIN
US8051111016
Symbol
SVRA
Sector
Industry

Key metrics

Market capitalization $697.91m
Enterprise Value $603.03m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 5.76
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-81.34m
Free Cash Flow (TTM) Free Cash Flow $-72.00m
Cash position $121.52m
EPS (TTM) EPS $-0.42
P/E forward negative
Short interest 6.87%
Show more

Is Savara, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Savara, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Savara, Inc. forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Savara, Inc. forecast:

Buy
100%

Financial data from Savara, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.27 0.27
108% 108%
-
-0.27 -0.27
108% 108%
-
- Selling and Administrative Expenses 20 20
64% 64%
-
- Research and Development Expense 61 61
83% 83%
-
-81 -81
78% 78%
-
- Depreciation and Amortization 0.27 0.27
108% 108%
-
EBIT (Operating Income) EBIT -81 -81
78% 78%
-
Net Profit -75 -75
76% 76%
-

In millions USD.

Don't miss a Thing! We will send you all news about Savara, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Savara, Inc. Stock News

Neutral
Business Wire
about 4 hours ago
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On September 25, 2024, Savara's Board of Directors granted the inducement awards to Braden Parker, who joined the Company as Chief Commercial Officer on September 24, 2024. The inducement a...
Neutral
Business Wire
about 12 hours ago
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the Savara Early Access Program, a molgramostim Expanded Access Program (EAP) for patients with aPAP. The program enables physicians to request molgramostim for eligible aPAP patients in select geographies where the product i...
Neutral
Business Wire
5 days ago
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, will host an analyst and investor webinar on September 30, 2024 from 8:30-9:30 a.m. ET to present data from the Phase 3 IMPALA-2 clinical trial of molgramostim inhalation solution (molgramostim) in autoimmune Pulmonary Alveolar Proteinosis (...
More Savara, Inc. News

Company Profile

Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.

Head office United States
CEO Matthew Pauls
Employees 37
Founded 1995
Website www.savarapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today